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Macrolides are the first-line treatment against bovine respiratory disease (BRD), and
are also used to treat infections in humans. The macrolide, tylosin phosphate, is often
included in the diet of cattle as a preventative for liver abscesses in many regions of the
world outside of Europe. This study investigated the effects of administering macrolides
to beef cattle either systemically through a single subcutaneous injection (therapeutic)
or continuously in-feed (subtherapeutic), on the prevalence and antimicrobial resistance
of Mannheimia haemolytica and Enterococcus spp. isolated from the nasopharynx and
faeces, respectively. Nasopharyngeal and faecal samples were collected weekly over
28 days from untreated beef steers and from steers injected once with tilmicosin
or tulathromycin or continuously fed tylosin phosphate at dosages recommended
by manufacturers. Tilmicosin and tulathromycin were effective in lowering (P < 0.05)
the prevalence of M. haemolytica, whereas subtherapeutic tylosin had no effect.
M. haemolytica isolated from control- and macrolide-treated animals were susceptible to
macrolides as well as to other antibiotics. Major bacteria co-isolated with M. haemolytica
from the nasopharynx included Pasteurella multocida, Staphylococcus spp., Acinetobacter
spp., Escherichia coli and Bacillus spp. With the exception of M. haemolytica and
P. multocida, erythromycin resistance was frequently found in other isolated species. Both
methods of macrolide administration increased (P < 0.05) the proportion of erythromycin
resistant enterococci within the population, which was comprised almost exclusively of
Enterococcus hirae. Injectablemacrolides impacted both respiratory and enteric microbes,
whereas orally administered macrolides only influenced enteric bacteria.
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INTRODUCTION
Bovine respiratory disease (BRD), commonly known as shipping
fever continues to be one of the most economically significant
health issues in feedlot cattle. The pathogenesis of BRD is mul-
tifactorial, being influenced by stress, immune status as well as
viral/bacterial interactions within the respiratory tract. Regardless
of what initiates the disease, Mannheimia haemolytica is consid-
ered to be the predominant bacterial pathogen associated with
BRD (Confer, 2009).
To reduce or treat BRD, antibiotics are commonly adminis-
tered to cattle upon arrival in North American feedlots. The use
of antimicrobial therapy to control BRD increases in high-density
feedlots where conditions are favorable for the introduction and
transmission of infectious microbes. The macrolides, tilmicosin
and tulathromycin are frequently administered subcutaneously
to high-risk cattle, either prophylactically, metaphylactically, or
therapeutically to cattle suffering from the disease. In North
America, the macrolide tylosin phosphate is also included in beef
cattle diets as a growth promoter and to prevent liver abscesses,
a practice banned in Europe. After ionophores and tetracycline,
macrolides are the most frequently used antimicrobials in cattle
production in Canada (CIPARS, 2013). In the United States, a
survey of 84% of the US feedlots revealed that about 42% of cattle
received tylosin in feed for 138–145 days whereas over two-thirds
of the cattle received injectable macrolides (USDA, 1999).
Macrolides belonging to the antimicrobial drug superfamily
MLSB (macrolide–lincosamide–streptogramin B) are classified
as category II antimicrobials by the WHO and Health Canada
(http://hc-sc.gc.ca/dhp-mps/vet/antimicrob/amr_ram_hum-med-
rev-eng.php) emphasizing their importance in treating infections
in humans. As reviewed by Gow (2005), as a proportion of total
DDDs (Defined Daily Dose) for humans, after penicillins (27%),
macrolides (20%) constitute the second most common systemic
antibacterial class dispensed by retail pharmacies in Canada,
followed by tetracyclines (14%), fluoroquinolones (12%), first-
and second-generation cephalosporins (10%).
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Although tilmicosin, tulathromycin and tylosin are exclusively
used in food animals, they belong to the same category II MLSB
superfamily as erythromycin, which is used in both humans, food
and companion animals. Despite having slight structural differ-
ences these drugs cross-select for resistance to all drugs of this
superfamily, including several drugs used to treat infections in
humans such as erythromycin and its derivatives azithromycin
and clarithromycin (Roberts, 2008; Desmolaize et al., 2011).
Consequently, use of macrolides in livestock could affect the
efficacy of these antibiotics in controlling infections in humans
through selection for resistance. Macrolide resistance can be con-
ferred by discrete point mutations at nucleotide A2058 and its
neighbours in the 23S rRNA, altering the main anchoring point
for these antibiotics (Schlünzen et al., 2001) or by methylation
of the A2058 at the N6 position as catalyzed by the Erm family
of methyltransferases (Skinner et al., 1983). Drug efflux systems
have also been shown to result in macrolide resistance (Roberts
et al., 1999).
Enterococci are common members of the normal gut flora
of both livestock and humans (Yost et al., 2011), but they can
also be important human pathogens as Enterococcus faecalis and
Enterococcus faecium are often implicated in nosocomial infec-
tions. Macrolide resistant enterococci have been isolated from
cattle and depending on the species, could potentially colonize
the intestinal tract of humans if they enter the food chain (Giraffa,
2002; Jensen et al., 2002).
The present study investigated and compared the response
of respiratory and digestive tract bacteria in feedlot cattle to
no antibiotic treatment or treatment with macrolide antibi-
otics at subtherapeutic (in-feed) or therapeutic (via injec-
tion) levels. Our specific objective was to evaluate the effects
of administering macrolides to beef cattle either systemi-
cally through a single subcutaneous injection (tilmicosin and
tulathromycin) or continuously in-feed (tylosin phosphate),
on the prevalence and the antimicrobial resistance profiles
of faecal Enterococcus spp., and M. haemolytica from the
nasopharynx.
MATERIALS AND METHODS
EXPERIMENTAL DESIGN
The study was conducted at the individual feeding barn facility
at the Lethbridge Research Centre (Lethbridge, Alberta, Canada)
using 40–eleven month old beef steers (394 ± 37 kg). All steers
originated from the same ranch and had not received antibi-
otics during their lifetime prior to their arrival at the Lethbridge
Research Centre. Steers were housed in individual pens with 10
replicate animals for each of the four treatments (1) control, no
antibiotics; (2) tilmicosin (Micotil® Elanco Animal Health) single
subcutaneous injection at 10mg/kg bodyweight (BW) on day 1;
(3) tulathromycin (Draxxin® Pfizer Animal Health, www.pfizer.
ca) single subcutaneous injection at 2.5mg/kg BW on day 1;
(4) tylosin phosphate (Tylan®, Elanco Animal Health, www.
elanco.ca) at 11 ppm in feed for the entire 28 day experimen-
tal period (Figure 1). Adjacent pens within the same treatment
group shared a common water trough and cattle within each
treatment were housed in separate, but otherwise identical wings
of the barn. Throughout the study, care of the steers was in
accordance with the guidelines set by the Canadian Council on
Animal Care (http://www.ccac.ca/).
DIET AND FEEDING
Steers were housed in individual pens and fed a typical forage-
based growing diet consisting of 70% barley silage, 25% barley
grain, and 5% supplement (Addah et al., 2011) on a dry matter
(DM) basis, for the entire experimental period (Figure 1). Steers
were fed once daily in a manner that ensured that all feed that
was allotted was consumed. To avoid cross contamination of feed,
tylosin was mixed with 5 kg of supplement and manually spread
over the surface of feed within each of the appropriate pens dur-
ing the morning feeding. All cattle were provided feed at the same
time each day with no feed remaining in the bunk prior to the
next feeding. Cattle assigned to the control treatment had no
access to medicated feed throughout the entire experiment and
were not injected with any antibiotics.
SAMPLING AND SAMPLE PROCESSING
Rectal faecal and nasopharyngeal swab samples were taken from
all 40 animals on arrival (day 0) at the facility, and then weekly
thereafter for 4 weeks and processed as follows:
Faecal samples
Rectal grab faecal samples were taken and used for subsequent
determination of antimicrobial resistant and total numbers of
enterococci bacteria. For the isolation of Enterococcus species
faecal samples (1 g) were diluted 1:5 in phosphate buffered
saline, from which serial dilutions were made up to 10−5 and
100µL of each dilution was spread-plated, in duplicate, onto
Bile-Esculin-Azide (BEA) agar plates. Dilutions 10−1 and 10−2
were also spread-plated onto BEA agar containing erythromycin
at a concentration of 8µg/mL of media (BEA+Ery) to iso-
late macrolide-resistant enterococci. Plates were incubated at
37◦C for 24 h and colonies from both BEA and BEA+Ery
plates were enumerated. Three to five presumptive Enterococcus
colonies per sample per media type were isolated and streak-
purified onto BEA or BEA+Ery plates accordingly. Purified
isolates were stored in glycerol stocks at −80◦C until further
characterized.
Nasopharyngeal swab samples
Nasopharyngeal swab samples were collected using a commer-
cially available deep, double guarded culture swab (Jorgensen
Laboratories, Inc., Loveland, CO, USA) from all 40 steers
on arrival at the beef-barn facility prior to administration of
antibiotics, and then weekly thereafter for 4 weeks following
antibiotic treatment. Swab samples were transported to the lab
on ice and immediately suspended in 0.7mL of Brain Heart
Infusion (BHI) broth. Aliquots (100µL) were cultured at 37◦C
for 16 h onto BAC-agar plates (tryptic soy agar plates con-
taining 5% sheep blood and 15µg/mL of bacitracin; Dalynn
Biologicals, Inc., Calgary, AB, Canada) with and without the
addition of erythromycin (Ery) 8µg/mL at 37◦C for 16 h.
Colonies (1–5) indicative of Mannheimia, were selected and
tested for catalase and oxidase activity as described previously
(Klima et al., 2011). Isolates that exhibited typicalM. haemolytica
Frontiers in Microbiology | Antimicrobials, Resistance and Chemotherapy May 2013 | Volume 4 | Article 133 | 2
Zaheer et al. Subtherapeutic vs. therapeutic macrolide use
FIGURE 1 | Experimental design. Immediately after first sample
collection on day 0 (d0) animals were administered appropriate
treatments and hence the same day is also referred as day 1,
denoting the beginning of the experimental period. Cattle had no
prior direct exposure to antibiotics prior to initiation of the
experiment.
colony morphology and were both catalase and oxidase posi-
tive were subsequently confirmed using a multiplex PCR assay
(Alexander et al., 2008). Confirmed M. haemolytica isolates
were stored at −80◦C in BHI broth containing 20% glyc-
erol for further characterization. Colonies that did not exhibit
morphology indicative of Mannheimia on BAC or BAC+Ery
agar plates were identified and 1–2 colonies representing each
morphotype were selected and stored at −80◦C in BHI broth
containing 20% glycerol until further characterized. Bacitracin
in BAC media inhibited the growth of the majority of gram
positive bacteria, thereby improving the likelihood of isolat-
ing M. haemolytica. Although bacitracin resistant gram positive
bacteria were co-isolated with Mannheimia, these isolates were
subsequently identified using 16S rRNA profiling as described
below.
CHARACTERIZATION OFMannheimia haemolytica AND CO-ISOLATED
NASOPHARYNGEAL BACTERIA
Confirmed M. haemolytica isolates were serotyped as previ-
ously described (Klima et al., 2011) with antisera prepared
in rabbits against formalin-killed whole cells of M. haemolyt-
ica reference strains UGCC G1 (serotype 1), UGCC G2
(serotype 2), ATCC 29697 (serotype 6), ATCC 29698 (serotype
7), and ATCC 29700 (serotype 9). Isolates were subject to
pulsed field gel electrophoresis (PFGE) profiling using SalI
restriction enzyme as previously described (Klima et al., 2011).
The 16S rRNA genes were PCR amplified from bacteria co-
isolated with M. haemolytica using universal bacterial 16S rRNA
gene primers 27F (5′-AGAGTTTGATCCTGGCTCAG-3′) and
1492R (5′-GGTTACCTTGTTACGACTT-3′) and subject to DNA
sequencing (Eurofins MWG Operon, Huntsville, Alabama, USA)
using one (27F) or both (27F and 1492R) primers.
ANTIBIOGRAMS
Disk susceptibility tests were conducted for Mannheimia in
accordance with the Clinical and Laboratory Standards Institute
documents M31-A3 and M45-A (CLSI, 2008a,b). The antimi-
crobials tested, suppliers and resistance breakpoints applied
are listed in Table 1. Reference strains Escherichia coli ATCC
35218, Staphylococcus aureus ATCC 25923, Streptococcus pneumo-
niae ATCC 49619, and M. haemolytica ATCC 33396 were used
as quality controls. Briefly, cultures grown on Muller–Hinton
agar supplemented with 5% defibrinated sheep blood (MHB;
16–18 h at 37◦C) were suspended into Muller–Hinton broth to
an absorbance reading between 0.125 and 0.145 at 625 nm. Using
sterile swabs, the prepared inocula were swabbed onto MHB
followed by the dispensation of the antibiotic containing disks
onto the plate surface. The plates were incubated at 37◦C in
ambient air, with the exception of S. pneumoniae ATCC 49619
which required cultivation in a 5% CO2 atmosphere for 24 h.
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Table 1 | Antimicrobial agents, suppliers, disk contents, and interpretative criteria used for disk susceptibility testing.
Antimicrobial Supplier Supplier code Disk content (µg) Zone diameter (mm) breakpointsc
S I R
Amoxicillin/clavulanic Acida BD AMC-30 20/10 ≥27 n/a ≤26
Ampicillina BD AM-10 10 ≥27 n/a n/a
Ceftiofurb BD XNL-30 30 ≥21 18–20 ≤17
Danofloxacinb Pfizer DNO 5 ≥22 n/a n/a
Erythromycina BD E-15 15 ≥27 25–26 ≤24
Florfenicolb BD FF-30 30 ≥19 15–18 ≤14
Gentamicinb BD GM-10 10 ≥15 13–14 ≤12
Oxytetracyclinea BD T-30 30 ≥23 n/a n/a
Spectinomycinb BD SPT-100 100 ≥14 11–13 ≤10
Sulfamethoxazolea/trimethoprim BD SXT 23.75/1.25 ≤24 n/a n/a
Tilmicosinb BD TIL-15 15 ≥14 11–13 ≤10
Tulathromycinb Pfizer TUL 30 ≥18 15–17 ≤14
aM45-A: Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria; approved guideline (CLSI, 2008b). Due to
the unavailability MIC breakpoints for Mannheimia spp., guidelines for Pasteurella spp. were followed.
bM31-A3: Performance standard for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; approved standard—third edition
(CLSI, 2008a).
cZone diameter value used to indicate susceptible (S), intermediate (I) and resistant (R), n/a, not available.
The resulting zones of inhibition were read using the BioMic V3
imaging system (Giles Scientific, Inc., Santa Barbara, CA, USA).
CHARACTERIZATION OF ENTEROCOCCI
The enterococci isolated from faecal samples were confirmed to
be Enterococcus spp. by PCR using primers Ent-ES-211-233-F
(5′-GHACAGAAGTRAAATAYGAAGG-3′) and Ent-EL-74-95-R
(5′-GGNCCTAABGTHACTTTNACTG-3′) and 130 select iso-
lates representing both erythromycin susceptible and resistant
categories were further analyzed for species identification by
pyrosequencing as described by Zaheer et al. (2012). Thirty
six select isolates were subject to PFGE profiling using SmaI
restriction enzyme using an adaptation of the procedure of
Turabelidze et al. (2000). Briefly, bacteria from overnight brain-
heart infusion-agar (BHI-agar) cultures were harvested using
sterile swabs and suspended in cell suspension buffer [100mM
Tris-HCl (pH 8.0) and 100mM EDTA], to an optical density
(OD) of 1.2–1.3 at 610 nm (1-cm light path). Aliquots (1ml
each) of the suspensions were centrifuged (10,000 × g) for
2min. in a microcentrifuge and 2/3rd of the supernatant was
removed from the tube. The bacterial pellet was resuspended in
the remaining supernatant, concentrating the cell suspension to
an OD610 of 3.6–4.0 (ca. 2.5 × 109 CFU/ml). An aliquot (100µL)
of cell suspension was added to an equal volume of lysis buffer
(50mM Tris-HCl (pH 8), 50mM EDTA, 625 U/ml mutanolysin,
2.5mg/ml lysozyme, 1.5mg/ml proteinase K, 20µg/ml RNase),
mixed gently and incubated at 37◦C for 10min. An equal vol-
ume of 1.2% molten SeaKem Gold agarose (FMC BioProducts,
Rockland, Maine) containing 1% sodium dodecyl sulfate was
added, the mixtures were poured in duplicate into 2-cm by 1-cm
by 1.5-mm reusable plug molds (Bio-Rad Laboratories, Hercules,
CA) and allowed to solidify at room temperature for 10min.
The duplicate plugs were added to a tube containing 1.8mL
of proteolysis solution [0.44 M EDTA (pH 8.0), 1% sarcosyl,
400µg/ml of proteinase K] and incubated with constant agita-
tion at 300 rpm for 2 h at 55◦C. Plugs were washed 3 times for
10min each in H2O (1.8mL), followed by 3 times for 10min
in TE (1.8mL) in a thermomixer set at 50◦C and 300 rpm. One
plug was cut in three equal slices latitudinally and two of the
gel slices were pre-incubated in 200µL of 1X restriction enzyme
buffer for 15min at 30◦C. DNA in the plugs was restricted
with 50 units of SmaI in a 200µL reaction mixture for 3 h at
25◦C. As a reference standard XbaI digested Salmonella serotype
Braenderup (H9812) plugs were prepared as previously described
(Klima et al., 2011).
The digested plugs were embedded in 1% SeaKem Gold low-
melting temperature agarose (Lonza Canada, Inc., Shawinigan,
QC) that was dissolved in 0.5 × TBE (45mM Tris, 45mM boric
acid, 1mM EDTA, pH 8.0). Prior to incorporation into the gel,
digested plugs were incubated with 200µl of 0.5 × TBE at room
temperature for 20min. The digested DNA were separated by
PFGE using a CHEF DRII device (Bio-Rad Laboratories Ltd.,
Mississauga, ON, Canada), at 12◦C. The voltage was maintained
at 6V/cm for a total of 21 h with switch times of 4–40 s for initial
12.5 h followed by switch times of 1.5–6 for 8.5 h. The gels were
run in 0.5 × TBE buffer containing 0.45mM thiourea. After elec-
trophoresis, gels were stained with ethidium bromide (1µg/ml)
in distilled water for 20min followed by three 20min washes with
distilled water. Gels were photographed with an AlphaImager
gel documentation system (Alpha Innotech Corp., St. Leandro,
CA). Fragment analysis was performed with BioNumerics V5.1
software (Applied Maths Inc., Austin, TX).
IDENTIFICATION OF MACROLIDE RESISTANCE DETERMINANTS
Erythromycin-resistant isolates were evaluated for the presence of
the commonly found macrolide resistance determinants erm(A),
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erm(B), erm(C), erm(F), erm(T), erm(X), mef (A) (http://faculty.
washington.edu/marilynr/) by PCR analyses. For generating PCR
template, a single bacterial colony was suspended in 50µL of TE
(10mM Tris.HCl pH 8.0, 1mM EDTA pH 8.0) and incubated
at 95◦C for 5min followed by centrifugation at 10,000× g for
5min. Supernatant (2µL) was used as template in a 20µL volume
PCR reaction mixture using PCR primers and reaction condi-
tions as described elsewhere (Chen et al., 2007; Szczepanowski
et al., 2009). The commercially available HotStarTaq Plus Master
Mix Kit (Qiagen Canada, Inc., Mississauga, ON, Canada) was
used according to manufacturer’s instructions. Plasmids con-
taining corresponding gene fragments previously cloned in our
laboratory were used as positive controls. Select PCR fragments
amplified from erythromycin resistant isolates originating from
the present study were verified by DNA sequencing.
STATISTICAL ANALYSIS
Data were analyzed using commercially available statistical analy-
sis software (SAS System forWindows, release 9.1.3, SAS Institute,
Cary, NC). Prevalence ofM. haemolytica and erythromycin resis-
tance in enterococci were analyzed using logistic methodology
within the GLIMMIX procedure of SAS, with treatment in the
model and day of sampling treated as a repeated measure. Model
adjusted means (LS means back-transformed to original scale)
and standard errors were reported and used to estimate the effi-
cacy of the antibiotic treatments for controlling M. haemolytica.
For all tests, the level of significance was set at P < 0.05.
ETHICS STATEMENT
Experiments with beef steers were conducted according to the
Canadian Council on Animal Care (CCAC) guidelines. The stud-
ies were approved by the institutional Animal Care Committee
(ACC), Lethbridge Research Centre, Agriculture and Agri-Food
Canada, under protocol number 1111. Antibiotics were admin-
istered or fed at levels approved by the Canadian Bureau of
Veterinary Drugs and recommended by the manufacturer and
used in accordance with industry practices.
RESULTS
Mannheimia haemolytica CHARACTERIZATION
A total of 274 suspect M. haemolytica isolates were obtained over
the duration of the study of which 260 were confirmed by mul-
tiplex PCR assay (Alexander et al., 2008). Isolates were obtained
from 29 out of the 40 steers used in the experiment. All of the
confirmed M. haemolytica isolates were serotyped and 160 (1–3
isolates perMannheimia positive animal per sampling event) were
tested for antimicrobial susceptibility using the disk diffusion
assay, and 65 (one isolate belonging to each of the M. haemolyt-
ica positive animals for each sampling event) were subjected to
PFGE.
Serotyping revealed that 89% (232/260) of the M. haemolytica
isolates that originated from 93% (27/29) of the positive ani-
mals were serotype 1, whereas 8.4% (22/260) of the isolates, all
of which originated from a single steer were serotype 2. Two per-
cent (5/260) of the isolates were identified as serotype 6, all of
which were obtained from a single steer on the 28th day post
treatment. Two main clusters were identified by PFGE analysis,
cluster A consisted primarily of serotype 1 isolates with only a sin-
gle serotype 6 isolate, whereas cluster B was comprised of serotype
2 isolates (Figure 2). Two sub-clusters, A1 and A2 were observed
within cluster A; A1 solely comprising serotype 1 isolates and A2
consisting of a mixture of serotype 1 and 6 (Figure 2).
The prevalence of M. haemolytica dropped substantially from
steers that were injected with tilmicosin or tulathromycin
as compared to levels prior to treatment (Figure 3A).
Compared to the control, the number of steers harboring
M. haemolytica was reduced (P < 0.05) by systemic treat-
ment with either tilmicosin or tulathromycin over the post
treatment sampling period (days 7–28). Compared to the
in-feed tylosin, tilmicosin and tulathromycin also resulted
in a reduction (P < 0.05) in number of cattle positive for
M. haemolytica (64 and 42%, respectively) (Figure 3B). In
disk diffusion assays, M. haemolytica isolates cultured with-
out erythromycin on primary isolation were all sensitive to
amoxicillin/clavulanic acid, ampicillin, ceftiofur, danofloxacin,
erythromycin, florfenicol, gentamicin, oxytetracycline, specti-
nomycin, trimethoprim/sulfamethoxazole, tilmicosin, and
tulathromycin.
CHARACTERIZATION OF BACTERIA CO-ISOLATED WITHM. haemolytica
The non-Mannheimia bacterial colonies originating from
nasopharyngeal samples cultured on BAC or BAC+Ery agar
plates were divided into 11 morphological groups (Table 2). The
16S rRNA gene sequences from 165 select isolates with 5–15
isolates representing each morphology group were subsequently
analyzed for genus/species identification through alignments
using “seqmatch” (http://rdp.cme.msu.edu/index.jsp) or BLAST
(http://blast.ncbi.nlm.nih.gov/). The morphotypes were found
to be very consistent with 16S rDNA sequence based bacterial
identification and therefore were used to define the identity
of collected isolates. One representative of each morphotype
per sampling event was used to determine bacterial prevalence.
Along with M. haemolytica (13%), other bacteria found in abun-
dance included Pasteurella multocida (25%), Staphylococcus spp.
(25%), Acinetobacter spp. (9%), E. coli/Shigella group (8%), and
Bacillus licheniformis (7%) (Figure 4). Among the Staphylococcus
spp., S. epidermidis, S. pasteuri, and S. cohnii were abundant
and collectively constituted 20% of isolated nasopharyngeal
bacterial species, with S. sciuri only occasionally isolated. These
Staphylococcus species had indistinguishable colony morpholo-
gies and thus collectively constituted one morphological group
(Table 2). Staphylococcus chromogenes was placed in a separate
morphological group due to its distinct yellow color and it
constituted 5% of isolated nasopharyngeal bacterial species.
Other species such as streptococci, Macrococcus casseolyticus
and Bacillus spp. including B. clausii and B. pumilus were less
abundant (Figure 4). However, collectively and irrespective
of morphotypes, Bacillus spp. constituted ∼14% of isolated
bacteria.
Erythromycin resistance was found in all isolated bacte-
rial species except M. haemolytica, P. multocida and other less
frequently isolated bacteria (Table 2). Of the seven macrolide
resistance genes tested by PCR, the erm(C) was predomi-
nantly found in Staphylococcus spp. (Table 2). With regard to
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FIGURE 2 | Dendrogram of PFGE SalI profiles from representative
M. haemolytica isolates collected weekly. As an example, sample ID
151-3-1 represents isolate #1 from 3rd sampling event (day 14 post
treatment) from animal #151. (Control: animal IDs 151–160; tilmicosin:
animal IDs 161–170; tulathromycin: animal IDs 171–180; tylosin: animal IDs
181–190).
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FIGURE 3 | (A) Percentage of animals positive for M. haemolytica for each
of the five sampling events over 28 days study period. (B) Mean
percentage of M. haemolytica prevalence in animals over the entire study
period. Means with different superscripts differ (P < 0.05).
other erythromycin-resistant isolates, no resistance determinants
matching any of the seven PCR primer pairs were amplified and
therefore were considered as “not detected”.
EVALUATION OF ENTEROCOCCI PRE- AND
POST-MACROLIDE-TREATMENT
Enterococci were isolated from all 40 animals (control and treat-
ment groups) on arrival (day 0), and weekly thereafter for
4 weeks (day 7, 14, 21, and 28). Enterococci colonies obtained
on BEA and BEA+Ery plates were enumerated and the propor-
tion of erythromycin resistant colonies was calculated for each
sample (Figure 5). Compared to the control group, antibiotic
treatment groups were 76 times more likely (P < 0.02) to have
erythromycin resistant enterococci over the study period (days
7–28). Similarly, for all treatment groups, post-treatment samples
from the entire study period were 66 times more likely to have
erythromycin resistant enterococci (P < 0.001) when compared
to pre-treatment (day 0) samples. No significant differences in
the incidence of erythromycin resistance were observed between
injectable (tilmicosin and tulathromycin) and in-feed (tylosin)
macrolides.
Speciation of 130 of the enterococci isolates collected from
day 0, 7, or 28 revealed that all were Enterococcus hirae with
the exception of two which were Enterococcus casseliflavus. Fifty
select isolates of erythromycin resistant enterococci from day 0
and day 7 sampling events were used for the identification of
erythromycin resistance determinants. Of the seven macrolide
resistance genes investigated via PCR only the erm(B) gene was
identified in enterococci isolates.
Table 2 | Bacteria co-isolated with M. haemolytica.
Morphotypes Morphology on BAC-agar plates Species identification based on 16S
rDNA sequencing
Ery resistance Resistance
determinant(s)
Mh Small, glossy, grey, beta-haemolytic Mannheimia haemolyticaa – –
1 Small/small-medium, round, glossy, white S. epidermidis, S. cohnii, S. pasteuri,
S. saprophyticus, S. sciuri
+ erm(C), erm(C),
erm(C), ND, ND
2 Large, mucoid, semi-transparent, grey-white Pasteurella multocida – –
3 Very small, dense, brown/pale,
alpha-haemolytic
Streptococcus/Bacillus + ND
4 Medium/large, wrinkly, crusty, fluid-filled,
beta-haemolytic
Bacillus licheniformis + ND
5 Medium/large, glossy, grey-white, mostly
beta-haemolytic
Escherichia coli/Shigella + –
6 Medium/large, rough edges, flat, granular Bacillus clausii/Bacillus spp. + ND
7 Small, glossy, grey/cream Acinetobacter lwoffii, Acinetobacter spp. + ND
8 Small/medium, glossy, pale-yellow Staphylococcus chromogenes NA ND
9 Small/medium, pale-yellow, concentric with
concave center
Macrococcus caseolyticus NA ND
10 Medium, yellowish, concentric circles, very
haemolytic, greenish
Bacillus pumilus NA ND
U Unique morphologies found occasionally Klebsiella, Neisseria spp., Paenibacillus
spp., uncultured bacteria
NA ND
aAlso confirmed by multiplex PCR assay (Alexander et al., 2008); NA, not available, as those morphology groups were less commonly found on BAC plates and not
found on BAC+Ery plates; ND, not determined (no positives detected in PCRs with any of the tested macrolide primer sets, see Materials and Methods).
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FIGURE 4 | Relative abundance of bacitracin resistant bacterial species isolated from nasopharynx over 28-days sampling period. One representative
of each morphology per animal per sampling event were used to determine bacterial species prevalence (n = 466).
FIGURE 5 | Proportion of erythromycin-resistant faecal enterococci
isolates for each of the five sampling events over 28 days study period,
with day 0 samples collected prior to antibiotic treatment. From day 7
onward, Control isolates had less resistance detected (P < 0.05) than
antibiotic treated groups, while resistance noted with injectable macrolides
(tilimicosin and tulathormycin) did not differ from that cattle fed tylosin.
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A representative 36 erythromycin resistant enterococci from
12 select animals from three sampling events (day 0, 7, and 28)
were subject to PFGE and produced three closely related clusters
(>85% similarity) (Figure 6). In eight of the twelve animals the
PFGE profiles from the three sampling events had >90% sim-
ilarity indicating that erythromycin resistant enterococci likely
consisted of a persistent clonal population.
DISCUSSION
The objective of this study was to evaluate and compare the effect
of in-feed subtherapeutic and injectable therapeutic administra-
tion of macrolides on antimicrobial susceptibility of indicator
bacteria from the digestive and respiratory tract of feedlot cattle.
For this purpose we selected faecal enterococci and M. haemolyt-
ica as our indicator bacteria for the digestive and respiratory
tract, respectively. Injectable macrolide antimicrobials such as
tilmicosin and tulathromycin are commonly used at therapeu-
tic levels in beef cattle production to prevent and treat BRD. The
macrolide, tylosin is frequently administered in-feed at subther-
apeutic doses for improving feed efficiency and for the reduc-
tion of liver abscesses caused by Fusobacterium necrophorum and
Actinomyces pyogenes (www.merckvetmanual.com). The subther-
apeutic administration of antibiotics has been hypothesized to
promote resistance development as bacteria are exposed to sub-
lethal concentrations of antibiotic for prolonged periods of time.
Consequently, the subtherapeutic administration of antibiotics
in animal feeds for growth promotion has been proposed as a
serious public health concern (Aarestrup and Wegener, 1999;
Wegener et al., 1999; McEwen and Fedorka-Cray, 2002). Over the
last 6–10 years the minimum inhibitory concentrations (MICs)
of tilmicosin and tulathromycin towards M. haemolytica have
markedly increased (Portis et al., 2012), questioning the contin-
ued effectiveness of these antibiotics against the etiological agents
of BRD. Furthermore, M. haemolytica could serve as a reservoir
of macrolide resistance genes, potentially disseminating them to
other respiratory pathogens.
Deep nasopharyngeal swabs were taken to isolateM. haemolyt-
ica as this procedure is quick, simple and relatively non-invasive.
In our study, a single systemic administration of therapeutic
levels of either tilmicosin or tulathromycin was effective in lower-
ing M. haemolytica in the nasopharynx of steers (Figures 3A,B).
According to the manufacturer, (ELANCO Animal Health,
Guelph, On, Canada, www.elanco.ca) injecting cattle with 10mg
of tilmicosin /kg of body weight results in lung concentrations
exceeding the MIC(3.12µg/mL) for M. haemolytica for at least
3 days, eliminating it from the respiratory tract for up to 6 days
(Frank et al., 2000). Tulathromycin is believed to accumulate
in neutrophils and alveolar macrophages (Siegel et al., 2004;
Cox et al., 2010), with peak lung levels of 4.1µg/mL occur-
ring in cattle 24 h after a single injection and concentrations
remaining above the MIC for M. haemolytica (2.0µg/mL) for
10 days (www.pfizer.ca). Our data demonstrated that 7 days post-
injection, M. haemolytica was detected in only one steer treated
with tulathromycin and none of the steers treated with tilimi-
cosin, whereas 60% of steers were positive for this bacterium upon
arrival (day 0). This suggests thatM. haemolytica in newly arrived
cattle were not macrolide resistant, an observation supported by
our inability to isolate erythromycin resistantM. haemolytica and
likely a reflection of the fact that these cattle had no previous
exposure to macrolides.
In contrast to injectable macrolides, tylosin had no effect on
the number of M. haemolytica in steers administered this antibi-
otic in feed as compared to cattle that received no antibiotics
(Figures 3A,B). This observation likely reflects differences in the
method and concentration of the antibiotic administered and the
sensitivity of M. haemolytica to tylosin. Tylosin is not effective at
penetrating the outer membrane of Gram-negative bacteria and
as a result its MIC (64µg/mL) against M. haemolytica is much
higher than either tilimicosin or tulathromycin (Andersen et al.,
2012). Tylosin is known to be widely distributed in body fluids
and tissues, but comparative pharmacokinetics of its distribution
in the digestive tract relative to the respiratory tract when it is
administered in feed are poorly characterized (Lewicki, 2006).
Mannheimia haemolytica isolated from animals belonging to
control and all three macrolide treatment groups throughout
the course of study were found to be susceptible to all tested
macrolides indicating that both therapeutic and subtherapeu-
tic administration did not contribute to macrolide resistance
in M. haemolytica during the study. Mannheimia haemolytica
isolated in the present study were also susceptible to all other
antibiotics tested (Table 2). While tilmicosin and tulathromycin
are generally effective against M. haemolytica, a few isolates orig-
inating from Germany, Japan and United States have shown
resistance to these antibiotics (Katsuda et al., 2009; Watts and
Sweeney, 2010; Michael et al., 2012). An integrative conjugative
element (ICE) has been identified in P. multocida that exhibits
high similarity to ICEs in P. multocida 36950, Histophilus somni
23364 and an ICE fragment within the incompleteM. haemolytica
PHL23 genome (Michael et al., 2012). This is a matter of con-
cern as P. multocida, M. haemolytica, and H. somni often share
the same ecological niche in the bovine respiratory tract and
exchange of this ICE element could lead to macrolide resistance
in these BRD pathogens as transfer of this element among P. mul-
tocida, M. haemolytica, and E. coli has been demonstrated in the
laboratory (Dabo et al., 2007; Watts and Sweeney, 2010).
The majority ofM. haemolytica isolates collected from asymp-
tomatic animals in this study were serotype 1 (Figure 2). The
PFGE profiles of serotype 1 and 6 isolates clustered together
with a ∼83% relatedness, a relationship observed previously
for these serotypes (Klima et al., 2011). The predominance of
a single serotype in the majority of steers is likely a reflec-
tion of sourcing them from the same isolated ranch in south-
ern Alberta and transporting them directly to the Lethbridge
Research Centre. This arrangement was necessary to ensure
that steers had no exposure to antibiotics prior to arrival.
Serotype 1 has frequently been linked to clinical disease and
both serotypes 1 and 6 are often isolated from cattle with BRD
(Zecchinon et al., 2005). However, none of the steers in the
present study exhibited clinical BRD. The BRD complex consists
of a bacteria (M. haemolytica, Pasteurella multocida, Histophulus
somni, Mycoplasma bovis) and viruses (Bovine Viral Diarrhea,
Infectious Bovine Rhinotracheitis, Bovine Respiratory Synctial
Virus, Parainfluenza Type-3 Virus) which together supress innate
immune responses and cause lung damage (Fulton, 2009; Pardon
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FIGURE 6 | Dendrogram of PFGE SmaI profiles from representative
erythromycin resistant enterococci from day 0, 7, and 28. As an example,
sample ID 153-ERY-5-1 represents isolate #1 collected from BEA+ERY plates
on 5th sampling event (day 28) from animal #153. (Control: animal IDs
151–160; tilmicosin: animal IDs 161–170; tulathromycin: animal IDs 171–180;
tylosin: animal IDs 181–190.
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et al., 2011). It seems likely that in this study the steers lacked the
infectious complex necessary for the development of BRD.
Pasturella multocida was the most ubiquitous bacterium
isolated from the nasopharynx of steers and in contrast to
M. haemolytica, prevalence of this bacterium was similar in
pre- and post-treatment groups. However, none of the isolated
P. multocida exhibited resistance to erythromycin. As P. multocida
were not enumerated, it is possible that macrolides reduced the
population of this bacterium. After P. multocida, Staphylococcus
spp. was most abundant with a relative abundances of S. epi-
dermidis > S. pasteuri > S. cohnii > S. sciuri > S. sapro-
phyticus. Staphylococci are ubiquitous Gram-positive bacteria
and are common in the microflora of skin and mucosal sur-
faces. Currently, there are 31 species recognized in the genus
Staphylococcus and about half of these are indigenous to humans
(Kloos and Bannerman, 1994). The role of some species, such as
S. epidermidis, S. saprophyticus, S. Pasteuri and S. cohni in human
disease has been well documented (Piette and Verschraegen,
2008; Savini et al., 2009). Consistent with previous studies
(Aarestrup et al., 2000a; Simeoni et al., 2008), the major-
ity of the erythromycin resistant Staphylococcus spp. harbored
erm(C).
Thirteen percent of the isolated nasopharyngeal bacteria were
M. haemolytica followed by Acinetobacter, Enterobacteriaceae
(Esherichia spp., Shigella spp.) and Bacillus spp. including
B. licheniformis and B. clausii. Most of these bacteria are rec-
ognized as part of normal flora of the skin, oropharynx and
perineum of healthy individuals. While erythromycin resistance
was found in the majority of isolated nasopharyngeal bac-
teria, macrolide determinants could only be detected in the
Staphylococcus group. The primers we used to detect seven
macrolide resistance genes would not be expected to capture all of
the genes potentially conferring resistance. For example, primers
for erythromycin resistance genes erm(D) and erm(34) previously
characterized from B. licheniformis and B. clausii, respectively
(Israeli-Reches et al., 1984; Bozdogan et al., 2004) were not
included in our panel. Although we observed no increase in the
diversity of erythromycin resistant nasopharyngeal bacteria in our
study, determinants in those bacteria that possessed them could
be disseminated into the broader environment.
Escherichia coli are commonly used as faecal indicator bacteria
to assess AMR, but we chose enterococci as E. coli are intrinsically
resistant to macrolides (Mao and Putterman, 1968). Enterococci
are common inhabitants of the normal gut flora of both live-
stock and humans (Yost et al., 2011). Outside of their normal
habitat, enterococci are viewed as pathogens and may present a
public health concern as they can be transmitted to humans from
other hosts or by ingestion of contaminated food or water (Heuer
et al., 2006; Marshall and Levy, 2011). Enterococci, in particular
E. faecalis and E. faecium are recognized as prevalent nosocomial
pathogens (Fisher and Phillips, 2009; van Schaik and Willems,
2010) with many isolates being resistant to multiple antibiotics
and capable of exchanging DNA with other bacteria (SchjØrring
and Krogfelt, 2011). In the present study we did not isolate either
E. faecalis or E. faecium, with E. hirae being the predominant
species isolated from cattle, a species infrequently associated with
hospital infections.
The present study revealed a significant increase in the propor-
tion of erythromycin resistant enterococci following macrolide
treatment regardless of the method of administration (Figure 5).
Oral administration of tylosin was expected to have a direct
impact on the enterococci population of the gut, but the occur-
rence of erythromycin resistant enterococci in cattle administered
injectable macrolides was equally marked. Studies submitted
to the Food and Drug Administration’s Center for Veterinary
Medicine (FDA/CVM) showed that with a single subcutaneous
dose of tilmicosin to cattle, 24% was recovered in the urine and
68% in the feces, whereas with tulathromycin, 50% was recov-
ered in the feces with 90% of this being in its original form. It
has been proposed that tulathromycin losses activity at pH ≤ 7.0,
(Food and Drug Administration’s Center for Veterinary, 2013),
but considering that the pH in intestinal digesta and in feces is
usually neutral or acidic (Allison et al., 1979; Canh et al., 1997),
our results would suggest that this antibiotic selected for resistant
enterococci within the intestinal tract. It is possible that the forage
rich diet used in our study resulted in intestinal contents having,
a pH above 7.0, allowing the concentration of tulathromycin in
digesta to exceed the MIC of enterococci. High forage diets in cat-
tle are known to increase colonic pH to ranges between 7.4 and 8.0
(Scott et al., 2000; Loy et al., 2001), but results could be quite dif-
ferent on high grain diets where the pH of digesta is considerably
lower.
Similar PFGE profiles were observed for erythromycin resis-
tant enterococci from both pre- and post-treatment samples
(Figure 6), suggesting that regardless of the method of admin-
istration, macrolides selected for erythromycin resistant ente-
rococci that were already in the digestive tract. Selection for
resistant enterococci combined with a reduction in susceptible
enterococci significantly increased the presence of erythromycin
resistant Enterococcus spp. within the digestive tract. This obser-
vation is of interest considering that the cattle used in this study
originated from a very isolated ranch and never had prior direct
exposure to macrolides. It would be interesting to examine the
persistence of this resistant population for a prolonged period
of time to understand population dynamics and to investigate
if the metabolic burden/cost of antibiotic resistance genes in the
absence of macrolides leads to a decline in resistance within the
enterococci population over time. As is typical in industry, cat-
tle in this study were treated with injectable macrolides early in
the feeding period. Considering that they would have been fed for
an additional 200 days prior to slaughter, loss of resistant entero-
cocci from the intestinal tract at later points in the feeding period
is a distinct possibility. However, resistant enterococci may persist
in cattle fed tylosin as this antibiotic is often administered for a
longer duration of the feeding period.
All of the isolated erythromycin resistant enterococci
contained erm(B), a gene coding for rRNA adenine N-6-
methyltransferase, which methylates the A2058 position of 23S
rRNA. Macrolide resistance in enterococci isolates from humans
and animal sources in Europe has been well documented (Jensen
et al., 1999; Aarestrup et al., 2001). Occurrence of macrolide
resistance in enterococci originating from swine is thought to
stem from the subtherapeutic use of tylosin (Jackson et al.,
2004). The co-existence of macrolide resistance genes with other
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antibiotic resistance genes has also been observed, most notably a
link between resistance to macrolides and vancomycin (Aarestrup
et al., 2000b), attributable to erm(B) and the vanA gene occurring
in close proximity on the same plasmid. The increased occur-
rence of both erm and tet (tetracycline resistance) genes in faecal
microbial communities from beef cattle fed subtherapeutic lev-
els of tylosin has also been identified (Chen et al., 2008). Linkage
of determinants for MLSB and chloramphenicol resistance has
also been found on a single conjugative plasmid in E. faecium
and dissemination of this cluster among streptogramin-resistant
enterococci occurs (Werner et al., 2000). Resistance to MLSB
antibiotics in Gram-positive cocci colonizing humans is now
recognized to be a serious problem, negatively affecting clinical
outcomes (Lim et al., 2002; DiPersio and DiPersio, 2006).
Regardless of the hypothesized prospects of subtherapeu-
tic administration of antimicrobials contributing towards AMR
development, there is limited and conflicting data as to the
extent that subtherapeutic vs. therapeutic drug administra-
tion contributes to livestock mediated antimicrobial resistance.
Studies have shown that subtherapeutic administration of tylosin
had no impact on the prevalence of erythromycin resistant
Campylobacter in feedlot cattle (Inglis et al., 2005), whereas
with broiler chickens the frequency of macrolide resistant
Campylobacter in cecal contents was increased with subtherapeu-
tic vs. therapeutic doses of tylosin (Ladely et al., 2007). These
discrepancies may reflect species-specific (cattle vs. chicken) dif-
ferences in gastrointestinal physiology and diet. Others have
found that short-term therapeutic use of chlortetracycline in the
diet was no less likely to select for resistant Salmonella popula-
tions than long-term subtherapeutic use (Kobland et al., 1987).
In-feed and subcutaneous administration of oxytetracycline were
also equally responsible for increasing the proportion of feedlot
cattle excreting tetracycline resistant E. coli in faeces (Checkley
et al., 2010).
The present study offers a comparison of subtherapeutic and
therapeutic drug administration with regards to the prevalence
of resistance among bacteria from two independent locations in
cattle. In conclusion, the injectable macrolides had impact on
both respiratory and enteric microbes whereas orally adminis-
tered macrolides only influenced enteric bacteria. Therapeutic
levels of tilmicosin and tulathromycin were effective in lower-
ing nasopharyngeal M. haemolytica, whereas the in-feed levels
of tylosin had no effect on the prevalence of this bacterium.
M. haemolytica isolates from control and macrolide treated ani-
mals were found to be susceptible to macrolides as well as
other antibiotics tested. The lack of AMR in M. haemolytica
may be attributed to the possible absence of AMR determinants
in Mannheimia as well as other closely related bacteria such as
P. multocida. Erythromycin resistance was detected in nasopha-
ryngeal bacteria co-isolated with M. haemolytica, regardless of
the treatment group. All three macrolides increased the occur-
rence of erythromycin resistance Enterococcus spp. within the
intestinal tract of cattle, but the species identified were not those
most frequently linked to nosocomial infections in humans. To
our knowledge this is the first report on increased occurrence of
macrolide resistance in enterococci after systemic macrolide usage
in cattle. It would be interesting to monitor the post-treatment
AMR resistance over a period of weeks to months beyond
treatment to determine if these macrolide-resistant enterococci
continue to persist within the faecal bacterial populations of
cattle.
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